Dr Nieva on the Rationale for Comparing ALK Inhibitors in ALK+ NSCLC

Jorge Nieva, MD, an associate professor of clinical medicine at the Keck School of Medicine of the University of Southern California, discussed key clinical implications from matched-adjusted indirect comparison data evaluating the efficacy and safety of crizotinib (Xalkori) vs alectinib (Alecensa), brigatinib (Alunbrig), and lorlatinib (Lorbrena) in patients with ALK-positive non–small cell lung cancer.

See our site for more exclusive insights from the 2025 Bridging the Gaps in Lung Cancer meeting! https://www.onclive.com/bridging-the-...

Website: https://www.onclive.com
Twitter:   / onclive  
Facebook:   / onclive  
LinkedIn:   / onclive